MacroGenics
MGNX
$1.27
Share price
0.00%
Change (1 day)
-68.80%
Change (1 year)
Categories
Revenue for MacroGenics (MGNX)
Revenue in 2025 (TTM): $0.15 Billion USD
According to MacroGenics's latest financial reports the company's current revenue (TTM 
) is $0.15 Billion USD. In 2024 the company made a revenue of $0.14 Billion USD an increase over the revenue in the year 2023 that were of $57.19 Million USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for MacroGenics from 2013 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | $0.15 B | 2.76% |
| 2024 | $0.14 B | 159.37% |
| 2023 | $57.19 M | -61.77% |
| 2022 | $0.14 B | 96.53% |
| 2021 | $76.11 M | -22.15% |
| 2020 | $97.76 M | 57.62% |
| 2019 | $62.02 M | 3.17% |
| 2018 | $60.12 M | -61.89% |
| 2017 | $0.15 B | 71.68% |
| 2016 | $91.88 M | -8.9% |
| 2015 | $0.10 B | 113.38% |
| 2014 | $47.26 M | -16.72% |
| 2013 | $56.75 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | $0.14 B | -5.23% | 🇺🇸 USA |
 Pfizer PFE | $62.46 B | 40,878.96% | 🇺🇸 USA |
 Merck MRK | $63.92 B | 41,836.14% | 🇺🇸 USA |
 Gilead Sciences GILD | $28.73 B | 18,750.99% | 🇺🇸 USA |
 Amgen AMGN | $34.12 B | 22,288.42% | 🇺🇸 USA |
 Eli Lilly LLY | $49.00 B | 32,048.64% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $47.63 B | 31,151.68% | 🇺🇸 USA |